STOCK TITAN

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Trevi Therapeutics (Nasdaq: TRVI), developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced its participation in three major investor conferences this April 2025.

The company will present at the following events:

  • 24th Annual Needham Virtual Healthcare Conference (April 7-10) with a corporate presentation on April 7 at 11:00-11:40 a.m. ET
  • Jones Healthcare and Technology Innovation Conference (April 8-9) in Las Vegas, with a presentation on April 9 at 11:00-11:20 a.m. PT
  • Piper Sandler Spring Biopharma Symposium (April 16-17) in Boston

Trevi Therapeutics (Nasdaq: TRVI), che sta sviluppando Haduvio™ (nalbufina ER orale) per la tosse cronica in pazienti con fibrosi polmonare idiopatica (IPF) e tosse cronica refrattaria (RCC), ha annunciato la sua partecipazione a tre importanti conferenze per investitori questo aprile 2025.

L'azienda presenterà ai seguenti eventi:

  • 24ª Conferenza Virtuale Annuale sulla Salute di Needham (7-10 aprile) con una presentazione aziendale il 7 aprile dalle 11:00 alle 11:40 ET
  • Conferenza sull'Innovazione Sanitaria e Tecnologica di Jones (8-9 aprile) a Las Vegas, con una presentazione il 9 aprile dalle 11:00 alle 11:20 PT
  • Simposio Primaverile Biopharma di Piper Sandler (16-17 aprile) a Boston

Trevi Therapeutics (Nasdaq: TRVI), que está desarrollando Haduvio™ (nalbufina ER oral) para la tos crónica en pacientes con fibrosis pulmonar idiopática (IPF) y tos crónica refractaria (RCC), ha anunciado su participación en tres importantes conferencias para inversores este abril de 2025.

La empresa presentará en los siguientes eventos:

  • 24ª Conferencia Virtual Anual de Salud de Needham (7-10 de abril) con una presentación corporativa el 7 de abril de 11:00 a 11:40 a.m. ET
  • Conferencia de Innovación en Salud y Tecnología de Jones (8-9 de abril) en Las Vegas, con una presentación el 9 de abril de 11:00 a 11:20 a.m. PT
  • Simposio de Primavera Biopharma de Piper Sandler (16-17 de abril) en Boston

Trevi Therapeutics (Nasdaq: TRVI)는 Haduvio™ (경구용 날부핀 ER)를 개발하고 있으며, 이는 특발성 폐섬유증(IPF) 및 난치성 만성 기침(RCC) 환자의 만성 기침 치료를 위해 사용됩니다. 2025년 4월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다.

회사는 다음 이벤트에서 발표할 예정입니다:

  • 제24회 니덤 가상 헬스케어 컨퍼런스 (4월 7-10일)에서 4월 7일 오전 11:00-11:40 ET에 기업 발표
  • 존스 헬스케어 및 기술 혁신 컨퍼런스 (4월 8-9일) 라스베가스에서 4월 9일 오전 11:00-11:20 PT에 발표
  • 파이퍼 샌들러 봄 생명과학 심포지엄 (4월 16-17일) 보스턴에서

Trevi Therapeutics (Nasdaq: TRVI), qui développe Haduvio™ (nalbuphine ER orale) pour la toux chronique chez des patients atteints de fibrose pulmonaire idiopathique (IPF) et de toux chronique réfractaire (RCC), a annoncé sa participation à trois grandes conférences pour investisseurs en avril 2025.

La société présentera lors des événements suivants :

  • 24ème Conférence Virtuelle Annuelle de Santé de Needham (7-10 avril) avec une présentation d'entreprise le 7 avril de 11h00 à 11h40 ET
  • Conférence sur l'Innovation en Santé et Technologie de Jones (8-9 avril) à Las Vegas, avec une présentation le 9 avril de 11h00 à 11h20 PT
  • Symposium Printanier Biopharma de Piper Sandler (16-17 avril) à Boston

Trevi Therapeutics (Nasdaq: TRVI), das Haduvio™ (orale Nalbuphine ER) zur Behandlung von chronischem Husten bei Patienten mit idiopathischer Lungenfibrose (IPF) und refraktärem chronischen Husten (RCC) entwickelt, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im April 2025 bekannt gegeben.

Das Unternehmen wird auf den folgenden Veranstaltungen präsentieren:

  • 24. Virtuelle Gesundheitskonferenz von Needham (7.-10. April) mit einer Unternehmenspräsentation am 7. April von 11:00 bis 11:40 Uhr ET
  • Jones Healthcare und Technologie Innovationskonferenz (8.-9. April) in Las Vegas, mit einer Präsentation am 9. April von 11:00 bis 11:20 Uhr PT
  • Piper Sandler Frühlings-Biopharma-Symposium (16.-17. April) in Boston

Positive
  • None.
Negative
  • None.

NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April.

24th Annual Needham Virtual Healthcare Conference
April 7-10, 2025
Corporate Presentation: April 7, 11:00-11:40 a.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, CCO
Register here to watch the live presentation.

Jones Healthcare and Technology Innovation Conference
April 8-9, 2025, Las Vegas, Nevada
Corporate Presentation: April 9, 11:00-11:20 a.m. PT
Trevi Presenter: Jennifer Good, President and CEO
Presentation available to in-person attendees.

Piper Sandler Spring Biopharma Symposium
April 16-17, 2025, Boston, Massachusetts
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, CDO

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is the first and only therapy in clinical development to show a statistically significant reduction in chronic cough across patients with both IPF and RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.  

Chronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. 

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
carlsonj@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences-302419110.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What investor conferences will Trevi Therapeutics (TRVI) attend in April 2025?

Trevi will attend three conferences: Needham Virtual Healthcare Conference (April 7-10), Jones Healthcare Conference in Las Vegas (April 8-9), and Piper Sandler Spring Biopharma Symposium in Boston (April 16-17).

What therapeutic product is TRVI developing and for which conditions?

TRVI is developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

When is Trevi's presentation at the Needham Healthcare Conference?

Trevi will present at the Needham Virtual Healthcare Conference on April 7, 2025, from 11:00 to 11:40 a.m. ET.

Which Trevi executives will attend the Jones Healthcare Conference in Las Vegas?

Jennifer Good, President and CEO, will present at the Jones Healthcare Conference in Las Vegas on April 9, 2025.

What is the schedule for TRVI's presentation at the Jones Healthcare Conference?

TRVI will present on April 9, 2025, from 11:00 to 11:20 a.m. PT at the Jones Healthcare Conference in Las Vegas.
Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Stock Data

572.36M
85.06M
0.94%
82.44%
4.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN